US Pharma MarketingLong ignored by drugmakers, preeclampsia is now a focus for WHO and biopharma
WHO releases preeclampsia roadmap; Comanche, DiaMedica, Avilar & ProFound developing treatments; Eli Lilly exploring the space targeting 42,000 annual maternal deaths. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
A pregnancy-related hypertension disorder that impacts millions of mothers and newborns each year is getting more attention from the top levels of public health organizations and a few biopharma companies.
The World Health Organization on ...
Source: Endpoints News